The Clinical and Vascular Characteristics of RNF213 c.14576G>A Variant-Related Intracranial Major Artery Disease in China.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Hindawi Country of Publication: Netherlands NLM ID: 8914585 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8584 (Electronic) Linking ISSN: 09534180 NLM ISO Abbreviation: Behav Neurol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : New York : Hindawi
      Original Publication: London : Clinical Neuroscience Publishers, c1988-
    • Subject Terms:
      Adenosine Triphosphatases/*genetics ; Intracranial Arterial Diseases/*genetics ; Ubiquitin-Protein Ligases/*genetics; Adenosine Triphosphatases/physiology ; Adult ; Asian People/genetics ; Biomarkers ; Case-Control Studies ; China ; Female ; Genetic Predisposition to Disease/genetics ; Genotype ; Humans ; Magnetic Resonance Angiography ; Male ; Middle Aged ; Mutation/genetics ; Polymorphism, Single Nucleotide/genetics ; Risk Factors ; Ubiquitin-Protein Ligases/physiology
    • Abstract:
      Background and Purpose: Recently, several studies indicated the c.14576G>A variant on the ring finger protein 213 (RNF213), a founder variant of moyamoya diseases (MMD), was associated with non-MMD intracranial major artery stenosis/occlusion (non-MMD ICASO). We proposed that RNF213 variant-related ICASO including MMD might be a special entity with its own characteristics based on a genetic background. The aim of the study was to learn the clinical and vascular features of RNF213 variant-related ICASO. Moreover, we tried to explore the clinical significance of a testing variant in ICASO patients in China.
      Methods: Clinical material and routine image data were collected in 160 Chinese patients with ICASO, including 41 verified MMD and 119 non-MMD. DNA samples were extracted, and the c.14576G>A variant on RNF213 was genotyped. Then, the clinical and vascular features were compared between the patients with and without a relevant variant. Furthermore, the patients with RNF213 mutation were performed with high resolution magnetic resonance imaging (HR-MRI) examination to conclude features of the artery wall.
      Results: There were 16 (10%) patients (including 9 MMD and 7 non-MMD ICASO) presenting a heterozygous c.14576G>A variant while none of homozygote was found. Compared to the patients without the c.14576G>A variant, the variant group had more female, less symptomatic patients, and more possibility of having collateral vessels in vascular imaging. In the symptomatic subgroup, there is no significant difference in clinical presentation ( p > 0.05) between two groups. However, RNF213 variant-related ICASO had lower scores in NIHSS (1.0 ± 3.0 vs. 3.9 ± 5.0, p < 0.05) but not in mRS. In the symptomatic subgroup, in addition, most of the HR-MRI images of variant ICASO (77.8%, 7 of 9) were characterized by a shrunken outer diameter, concentric thickening vessel wall, and collateral vessel structures on the stenotic portion, which was prone to be diagnosed as HR-MMD (a MMD diagnosis diagnosed by HR-MRI). The rest of the two variants showed a relatively eccentric luminal narrow, normal outer diameter without collateral vessel findings, identified as HR-ICAD (intracranial atherosclerotic disease diagnosed by HR-MRI).
      Conclusions: Our study demonstrated that the c.14576G>A variant on RNF213 may be a biomarker to good outcome of ICASO in Chinese. The variant-related ICASO was characterized by both features of MMD and ICAD diagnosed by HR-MRI.
    • References:
      J Clin Neurosci. 2003 Jan;10(1):30-4. (PMID: 12464517)
      Cerebrovasc Dis. 2005;20 Suppl 2:75-83. (PMID: 16327256)
      Stroke. 2008 Aug;39(8):2396-9. (PMID: 18535283)
      Int J Stroke. 2006 Aug;1(3):158-9. (PMID: 18706036)
      J Hum Genet. 2011 Jan;56(1):34-40. (PMID: 21048783)
      Arch Neurol. 2011 Mar;68(3):338-42. (PMID: 21403018)
      PLoS One. 2011;6(7):e22542. (PMID: 21799892)
      Neurology. 2012 Mar 13;78(11):803-10. (PMID: 22377813)
      Stroke. 2012 Dec;43(12):3371-4. (PMID: 23010677)
      PLoS One. 2012;7(10):e48179. (PMID: 23110205)
      Blood Press. 2013 Aug;22(4):193-278. (PMID: 23777479)
      Eur J Neurol. 2013 Sep;20(9):1311-8. (PMID: 23789981)
      Stroke. 2013 Oct;44(10):2894-7. (PMID: 23970789)
      Stroke. 2014 Nov;45(11):3200-7. (PMID: 25278557)
      Neurosci Lett. 2015 Jan 1;584:77-82. (PMID: 25459282)
      Semergen. 2014 Sep;40 Suppl 4:11-8. (PMID: 25595348)
      Semergen. 2014 Sep;40 Suppl 4:19-25. (PMID: 25595349)
      Stroke. 2015 Mar;46(3):697-703. (PMID: 25628303)
      PLoS One. 2015 Jun 30;10(6):e0130663. (PMID: 26125557)
      J Neurosurg. 2016 May;124(5):1221-7. (PMID: 26430847)
      PLoS One. 2016 Jun 02;11(6):e0156607. (PMID: 27253870)
      Arch Neurol. 1969 Mar;20(3):288-99. (PMID: 5775283)
      Stroke. 1995 Jan;26(1):14-20. (PMID: 7839388)
      Clin Neurol Neurosurg. 1997 Oct;99 Suppl 2:S238-40. (PMID: 9409446)
    • Accession Number:
      0 (Biomarkers)
      EC 2.3.2.27 (RNF213 protein, human)
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
      EC 3.6.1.- (Adenosine Triphosphatases)
    • Publication Date:
      Date Created: 20190418 Date Completed: 20191126 Latest Revision: 20221207
    • Publication Date:
      20231215
    • Accession Number:
      PMC6434291
    • Accession Number:
      10.1155/2019/7908392
    • Accession Number:
      30992731